DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform

/in

New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress experimentally London, UK – 1 October 2026 – DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform. […]

Read more

Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline

/in

Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership HORGEN, Switzerland, October 1, 2026 – Numab Therapeutics (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, today announced the appointment of Rajesh Chopra, M.D., PhD, as Chief Scientific Officer. Read more…

Read more

Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition

/in

In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in lean muscle mass and a reduction in fat mass Data provide first human proof-of-mechanism and support Atrogi’s planned Phase 2 trial expected […]

Read more

R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

/in

Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia in patients on dialysis Investment comes ahead of Phase 2b topline data, expected in H1 2027 Redwood City, California […]

Read more

Oncoinvent to present three abstracts at EANM and ESMO 2026

/in

Oslo, Norway – 30 September 2026 – Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that three abstracts from its Radspherin® program have been accepted for presentation at the European Association of Nuclear Medicine (EANM) […]

Read more
© Optimum Strategic Communications.